AMSTERDAM, January 6 /PRNewswire/ -- Elsevier, the world's leading publisher of scientific, technical and medical information products and services, announced today that fifty prestigious titles from the Elsevier Doyma Spanish Medical Collection are available on ScienceDirect, its online scientific research platform.
Doyma, the leading Spanish language medical publisher acquired by Elsevier in 2005, publishes approximately 5,000 high quality papers every year. The inclusion of Elsevier Doyma titles on ScienceDirect will allow more researchers across the world to access these articles.
To date, the Elsevier Doyma collection has only been available through http://www.doyma.es and http://www.elsevierinstituciones.com and the narrow distribution as well as Spanish language nature of these platforms has limited access. The thousands of authors represented in the Elsevier Doyma collection will now enjoy greater market visibility, increasing the potential for research collaboration and recognition. In addition, many of the articles will now include English abstracts benefiting non-Spanish speaking researchers.
The Elsevier Doyma Spanish Medical Collection represents a wide range of high-quality journals, commented Rafael Sidi, Vice President, Product Management, ScienceDirect. We are excited to include these titles on ScienceDirect giving them more visibility in the global research community.
The addition of the Spanish Medical Collection follows the successful launch of Elsevier's Masson French Medical titles early 2008 and contributes to the evolution of the ScienceDirect platform into a comprehensive and complete source of global scientific knowledge.
About ScienceDirect
Over a quarter of the world's full text scientific, technical and medical (STM) peer-reviewed articles - managed by renowned editors, written by respected authors and read by researchers from around the globe - are available in one place: ScienceDirect.
Elsevier's extensive and unique full-text collection covers authoritative titles from the core scientific literature including high impact factor titles such as THE LANCET, Cell and Tetrahedron. Over nine million articles are available online, including Articles in Press which offer online access to recently accepted manuscripts. The critical mass of trusted information available on ScienceDirect is unsurpassed. Coverage includes over 2,500 journals published by Elsevier and dynamic linking to journals from approximately 2,000 STM publishers through CrossRef. An expanding program of online major reference works, handbooks, book series and over 4,400 eBooks in all fields of science seamlessly interlinks with primary research referenced in journal articles.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
CONTACT: Malkie Bernheim/ Melanie Nadeau Padilla Speer Beardsley +1-212-752-8338 mbernheim@psbpr.com/ mnadeau@psbpr.com
CONTACT: Malkie Bernheim/ Melanie Nadeau, Padilla Speer Beardsley, +1-212-752-8338, mbernheim@psbpr.com/ mnadeau@psbpr.com
Comments